Hypothesis 1: 8 cycles of a taxane is not inferior to 4 cycles of AC followed by 4 cycles of a taxane. Hypothesis 2: One of the taxanes is superior or equivalent to the other.
To verify these hypotheses, we analyzed disease-free survival as the primary endpoint and overall survival and relapse-free survival as secondary endpoints. To adjust for multiplicity, a two-sided significance level of 0.5% was used to verify superiority, and a one-sided significance level of 0.5% (1% for a two-sided test) was used to verify inferiority. For the estimation of hazard ratios, these values correspond to calculating a two-sided confidence interval of 99.5% and a two-sided confidence interval of 99%, respectively. For hypothesis 1, if the upper limit of the confidence interval for the hazard ratio with a taxane alone relative to that with AC + a taxane is 1.321 or less, a taxane alone is proven to be equivalent to AC + a taxane. For hypothesis 2, if the confidence interval of the hazard ratio for either taxane is not 1, one of the two taxanes is shown to be superior to the other. 
Demographics and Baseline Characteristics
Phase III two by two factorial comparison of Doxorubicin and Cyclophosphamide followed by a taxane vs. a taxane alone, and Paclitaxel vs. Docetaxel in operable node positive breast cancer -results of the first interim analysis of N-SAS BC02 trial, Japan. In the subset of HER2 positive patients, 4 cycles of AC followed by 4 cycles of a 4 cycles of AC followed by 4 cycles of a taxane taxane produced superior DFS as compared with 8 cycles of a 8 cycles of a taxane taxane. This is not observed in patients with HER2 negative patients. ) .
The expression of HER2 may be associated with a benefit from the addition of Anthracycline containing regimens. No. 4103
